Beacon Pointe Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Beacon Pointe Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$575K	Sell	12,085 -851	-7%	-$44.9K	﹤0.01%	1234
2025 Q4	$678K	Buy	12,936 +110	+0.9%	+$6.59K	﹤0.01%	964
2025 Q3	$831K	Buy	12,826 +5,380	+72%	+$309K	0.01%	833
2025 Q2	$362K	Buy	+7,446	New	+$288K	﹤0.01%	989
2024 Q2	–	Sell	-6,334	Closed	-$432K	–	1295
2024 Q1	$432K	Buy	6,334 +2,566	+68%	+$184K	﹤0.01%	971
2023 Q4	$236K	Buy	+3,768	New	+$208K	﹤0.01%	1157

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Beacon Pointe Advisors's CRSP Position: Q1 2026 in Review

Beacon Pointe Advisors reduced its CRISPR Therapeutics (CRSP) stake by 6.6% in Q1 2026, selling an estimated $44.9K and leaving 12,085 shares worth $575K. The position accounts for ﹤0.01% of the portfolio, ranked #1234.

Beacon Pointe Advisors first reported a position in CRSP in Q4 2023 and has held it in 6 quarters since. The position peaked at $831K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Beacon Pointe Advisors held 12,085 shares of CRISPR Therapeutics worth $575K as of Q1 2026.
Beacon Pointe Advisors sold 851 CRISPR Therapeutics shares in Q1 2026, an estimated $44.9K.
CRISPR Therapeutics made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q1 2026, its #1234 holding.
Beacon Pointe Advisors first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 6 quarters since.
Beacon Pointe Advisors's CRISPR Therapeutics position peaked at $831K in Q3 2025.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.